| Obinutuzumab studied in …STUDIED_INderived200 of 260show all (up to 200) |
|---|
| → studied in | NCT01414855Phase 2 · completed A Study of Obinutuzumab [RO5072759 (GA101)] in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER) · 260 trials list this drug (128 active) | — | — | B-Cell Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06649812Phase 2 · recruiting Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma · 260 trials list this drug (128 active) | — | — | Diffuse Large B-Cell Lymphoma,High Grade B-Cell Lymphoma,T-Cell/Histiocyte-Rich Large B-Cell Lymphoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07847957Phase 1/Phase 2 · not yet recruiting Roginolisib Plus Obinutuzumab + Venetoclax in R/R CLL · 260 trials list this drug (128 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03223610Phase 1/Phase 2 · recruiting Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma · 260 trials list this drug (128 active) | — | — | Lymphoma,Non-Hodgkin Lymphoma,Burkitt Lymphoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03462719Phase 3 · active not recruiting A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) · 260 trials list this drug (128 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04269902Phase 3 · recruiting Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study · 260 trials list this drug (128 active) | — | — | Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05100862Phase 3 · active not recruiting A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma · 260 trials list this drug (128 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06073821Phase 3 · active not recruiting Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL) · 260 trials list this drug (128 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06252675Phase 2 · recruiting Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma · 260 trials list this drug (128 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06943872Phase 3 · recruiting A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL) · 260 trials list this drug (128 active) | — | — | Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05783596Phase 2 · active not recruiting Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma · 260 trials list this drug (128 active) | — | — | Follicular Lymphoma,Indolent Non-Hodgkin Lymphoma,Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06284122Phase 3 · active not recruiting Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5 · 260 trials list this drug (128 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02992522Phase 1 · active not recruiting Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma · 260 trials list this drug (128 active) | — | — | B-Cell Malignant Neoplasm,Burkitt Lymphoma,Diffuse Large B-Cell Lymphoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06213311Phase 2 · recruiting A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma · 260 trials list this drug (128 active) | — | — | B-Cell Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06175000Phase 2 · recruiting Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response · 260 trials list this drug (128 active) | — | — | Primary Central Nervous System Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02537613Phase 1 · active not recruiting A Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia · 260 trials list this drug (128 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05861050Phase 1/Phase 2 · suspended Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma · 260 trials list this drug (128 active) | — | — | Mantle Cell Lymphoma,Blastoid Variant Mantle Cell Lymphoma,Pleomorphic Variant Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02629809Phase 2 · active not recruiting Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients With Chronic Lymphocytic Leukemia · 260 trials list this drug (128 active) | — | — | Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04889716Phase 2 · active not recruiting CAR-T Followed by Bispecific Antibodies · 260 trials list this drug (128 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06291220Phase 1 · active not recruiting A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) · 260 trials list this drug (128 active) | — | — | Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06634589Phase 1/Phase 2 · recruiting A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies · 260 trials list this drug (128 active) | — | — | Malignant Neoplasm,B-Cell Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06806033Phase 2 · recruiting Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL · 260 trials list this drug (128 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04169737Phase 2 · recruiting Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma · 260 trials list this drug (128 active) | — | — | Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07799220Phase 2 · not yet recruiting A Study of Zanubrutinib, Obinutuzumab, and Sonrotoclax in People With Mantle Cell Lymphoma · 260 trials list this drug (128 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05326308recruiting Zanubrutinib in Patients With Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma and Follicular Lymphoma · 260 trials list this drug (128 active) | — | — | Chronic Lymphocytic Leukemia,Follicular Lymphoma,Marginal Zone Lymphoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06561360Phase 2 · recruiting A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL) · 260 trials list this drug (128 active) | — | — | Hairy Cell Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07003295Phase 2 · recruiting Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy · 260 trials list this drug (128 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06624085Phase 1 · recruiting A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma · 260 trials list this drug (128 active) | — | — | Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03824483Phase 2 · active not recruiting Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL) · 260 trials list this drug (128 active) | — | — | Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05533775Phase 1/Phase 2 · recruiting A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma · 260 trials list this drug (128 active) | — | — | Mature B-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06084936Phase 3 · recruiting A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma · 260 trials list this drug (128 active) | — | — | Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05057494Phase 3 · active not recruiting A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma · 260 trials list this drug (128 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07502872Phase 2 · not yet recruiting TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma · 260 trials list this drug (128 active) | — | — | B-Cell Malignant Neoplasm,Lymphoma,Diffuse Large B-Cell Lymphoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06108232Phase 2 · recruiting Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma · 260 trials list this drug (128 active) | — | — | Neoplasm,Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03701282Phase 3 · active not recruiting Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia · 260 trials list this drug (128 active) | — | — | Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03737981Phase 3 · active not recruiting Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia · 260 trials list this drug (128 active) | — | — | Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07520006Phase 1/Phase 2 · recruiting Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies · 260 trials list this drug (128 active) | — | — | B-Cell Malignant Neoplasm,Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04077723Phase 1/Phase 2 · active not recruiting A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma · 260 trials list this drug (128 active) | — | — | Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02475681Phase 3 · active not recruiting Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL · 260 trials list this drug (128 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03410875Phase 2 · active not recruiting A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell Leukemia · 260 trials list this drug (128 active) | — | — | Leukemia,Hairy Cell Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06970743Phase 3 · active not recruiting A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors · 260 trials list this drug (128 active) | — | — | Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04515238Phase 2 · active not recruiting Sequential Regimen of Bendamustine Followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in Patients With Relapsed/Refractory CLL · 260 trials list this drug (128 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05197192Phase 3 · recruiting A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL · 260 trials list this drug (128 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07724457Phase 2/Phase 3 · not yet recruiting Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit Lymphoma · 260 trials list this drug (128 active) | — | — | Burkitt Lymphoma,High Grade B-Cell Lymphoma with MYC and BCL2 Rearrangements | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07774234Phase 2 · not yet recruiting Sonrotoclax, Glofitamab, Gemcitabine, and Oxaliplatin for Relapsed or Refractory Large B-Cell Lymphoma · 260 trials list this drug (128 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03198026Phase 2 · active not recruiting Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas · 260 trials list this drug (128 active) | — | — | Non-Hodgkin Lymphoma,Indolent Non-Hodgkin Lymphoma,Splenic Marginal Zone Lymphoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05169515Phase 1 · active not recruiting A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma · 260 trials list this drug (128 active) | — | — | Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06762431Phase 1/Phase 2 · recruiting Phase I/II Open-label Study Evaluating The Safety And Efficacy of Concomitant Administration of Anti-CD19 CAR T-cell Therapy and Lenalidomide in Refractory/Relapsed Chronic Lymphocytic Leukemia Patients. · 260 trials list this drug (128 active) | — | — | Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06849713Phase 2 · recruiting Zanubrutinib, Obinutuzumab, Sonrotoclax (BOSon) or BGB-16673, Obinutuzumab, Sonrotoclax (DOSon) in TN CLL/SLL · 260 trials list this drug (128 active) | — | — | Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02846623Phase 2 · active not recruiting Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome · 260 trials list this drug (128 active) | — | — | Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06191744Phase 3 · active not recruiting Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma · 260 trials list this drug (128 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06967610Phase 2 · recruiting Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL). · 260 trials list this drug (128 active) | — | — | Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03075696Phase 1/Phase 2 · active not recruiting A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma · 260 trials list this drug (128 active) | — | — | Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06765317Phase 2 · recruiting A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma · 260 trials list this drug (128 active) | — | — | Diffuse Large B-Cell Lymphoma,High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07719556Phase 2 · recruiting Orelabrutinib Combined With Obinutuzumab and Short-Course Venetoclax in Patients With Treatment-Naïve Mantle Cell Lymphoma (MCL) · 260 trials list this drug (128 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07719855Phase 3 · not yet recruiting A Multicenter, Prospective, Open-Label, Randomized Controlled Clinical Study of Orelabrutinib Combined With Obinutuzumab and Lenalidomide Versus Obinutuzumab Plus Chemotherapy for Treatment-Naive Follicular Lymphoma · 260 trials list this drug (128 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04970901Phase 1 · active not recruiting A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7) · 260 trials list this drug (128 active) | — | — | B-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07711483Phase 2 · not yet recruiting GLORY: Glofit-GemOx With Liso-Cel For Lymphoma · 260 trials list this drug (128 active) | — | — | B-Cell Malignant Neoplasm,Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07599423Phase 2 · not yet recruiting A Study of Glofitamab Plus GemOx Compared With Standard of Care in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma · 260 trials list this drug (128 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06558604Phase 2 · recruiting Phase II Study of Glofitamab With Venetoclax +/- Zanubrutinib in High-risk Mantle-cell Lymphoma · 260 trials list this drug (128 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03269669Phase 2 · active not recruiting Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma · 260 trials list this drug (128 active) | — | — | Follicular Lymphoma,Grade 1 Follicular Lymphoma,Grade 2 Follicular Lymphoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07690891Phase 2 · not yet recruiting Nemtabrutinib With Venetoclax and Obinutuzumab in Patients With Chronic Lymphocytic Leukemia · 260 trials list this drug (128 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04408638Phase 3 · active not recruiting A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma · 260 trials list this drug (128 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04447768Phase 2 · active not recruiting The Combination of Venetoclax and Obinutuzumab in People With Chronic Lymphocytic Leukemia (CLL) · 260 trials list this drug (128 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03533283Phase 1/Phase 2 · active not recruiting An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma · 260 trials list this drug (128 active) | — | — | Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06922604Phase 1 · suspended Glofitamab With Obinutuzumab Pre-treatment for the Treatment of Central Nervous System Lymphoma · 260 trials list this drug (128 active) | — | — | Primary Central Nervous System Lymphoma,Secondary Central Nervous System Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05653271Phase 1 · completed ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies · 260 trials list this drug (128 active) | — | — | B-Cell Malignant Neoplasm,Non-Hodgkin Lymphoma,Burkitt Lymphoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06824701Phase 1 · active not recruiting Tazemetostat in Combination With Zanubrutinib and Anti-CD20 Monoclonal Antibody in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma · 260 trials list this drug (128 active) | — | — | B-Cell Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07674810Phase 2 · not yet recruiting A Phase 2 Trial Of The Combination Of Zanubrutinib, Sonrotoclax, And Obinutuzumab For Patients With Treatment-Naïve Chronic Lymphocytic Leukemia · 260 trials list this drug (128 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03198650Phase 1 · completed A Phase 1 Study of Acalabrutinib in Japanese Adult Patients With Advanced B-cell Malignancies · 260 trials list this drug (128 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06544785Phase 2 · recruiting Zanubrutinib With Obinutuzumab in Untreated Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma · 260 trials list this drug (128 active) | — | — | Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03516617Phase 2 · recruiting Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma · 260 trials list this drug (128 active) | — | — | Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03872180Phase 2 · active not recruiting Bendamustine, Obinutuzumab, and Venetoclax in Patients With Untreated Mantle Cell Lymphoma · 260 trials list this drug (128 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04277637Phase 1 · active not recruiting Study of Bcl-2 Inhibitor Sonrotoclax (BGB-11417) in Participants With Mature B-Cell Malignancies · 260 trials list this drug (128 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02427451Phase 1/Phase 2 · active not recruiting Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia · 260 trials list this drug (128 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04505254Phase 2 · active not recruiting Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia · 260 trials list this drug (128 active) | — | — | Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07634289Phase 2 · not yet recruiting Radiotherapy in Combination With Glofitamab in Relapsed/Refractory Diffuse Large B Cell Lymphoma · 260 trials list this drug (128 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04722172Phase 2 · active not recruiting A Study on Limiting Treatment Time With Acalabrutinib Combined With Obinutuzumab in People With CLL or SLL · 260 trials list this drug (128 active) | — | — | Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07624799Phase 2 · not yet recruiting Fixed Duration Treatment With Combined Pirtobrutinib and Short Course Immuno-chemotherapy in Fit Patients With Previously Untreated Symptomatic Chronic Lymphocytic Leukemia (CLL). · 260 trials list this drug (128 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04739813Phase 1 · active not recruiting Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma · 260 trials list this drug (128 active) | — | — | Lymphoma,Non-Hodgkin Lymphoma,Burkitt Lymphoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07613788Phase 2 · not yet recruiting Rimegepant Plus Glofitamab and CD19 CAR-T Therapy in R/R LBCL · 260 trials list this drug (128 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05169658Phase 2 · completed Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma · 260 trials list this drug (128 active) | — | — | Non-Hodgkin Lymphoma,Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue,Indolent B-Cell Non-Hodgkin Lymphoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06504199Phase 2 · active not recruiting Obinutuzumab, Zanubrutinib, and Lenalidomide Followed Short-Cycle of Obinutuzumab and Cytarabine in Newly Diagnosed Mantle Cell Lymphoma · 260 trials list this drug (128 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07261163Phase 2 · recruiting Obinutuzumab, Zanubrutinib, and Lenalidomide in First-line Treatment of Mantle Cell Lymphoma · 260 trials list this drug (128 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03322865Phase 2 · active not recruiting Obinutuzumab in Marginal Zone Lymphoma · 260 trials list this drug (128 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05896163Phase 1/Phase 2 · terminated A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab) When Given Together In People With Relapsed Or Refractory Diffuse Large B Cell Lymphoma. · 260 trials list this drug (128 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05848765Phase 2 · recruiting Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy · 260 trials list this drug (128 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04608318Phase 3 · active not recruiting Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL) · 260 trials list this drug (128 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05536349Phase 2 · recruiting Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT) · 260 trials list this drug (128 active) | — | — | Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03863184Phase 2 · active not recruiting Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL · 260 trials list this drug (128 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03341520Phase 2 · completed Gazyvaro and Low Dose Radiotherapy in Early Stage Follicular Lymphoma · 260 trials list this drug (128 active) | — | — | Grade 1 Follicular Lymphoma,Grade 2 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04450173Phase 2 · active not recruiting Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma · 260 trials list this drug (128 active) | — | — | Grade 1 Follicular Lymphoma,Grade 2 Follicular Lymphoma,Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04560322Phase 2 · recruiting Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL · 260 trials list this drug (128 active) | — | — | Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06428019Phase 3 · recruiting A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) · 260 trials list this drug (128 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05798156Phase 2 · active not recruiting Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP · 260 trials list this drug (128 active) | — | — | Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06192888Phase 1 · active not recruiting A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma · 260 trials list this drug (128 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07480850Phase 2 · active not recruiting Efficacy and Safety of Glofitamab Combined With GemOxin the Treatment of Refractory Diffuse Large B-Cell Lymphoma · 260 trials list this drug (128 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04703686Phase 2 · completed Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy · 260 trials list this drug (128 active) | — | — | Transformed B-Cell Non-Hodgkin Lymphoma,Indolent Adult Non-Hodgkin Lymphoma,Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07218510Phase 2 · recruiting Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial · 260 trials list this drug (128 active) | — | — | Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04285567Phase 3 · completed A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation · 260 trials list this drug (128 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05650723Phase 2 · active not recruiting Zanubrutinib and Venetoclax as Initial Therapy for Chronic Lymphocytic Leukemia (CLL) With Response-based Obinutuzumab · 260 trials list this drug (128 active) | — | — | Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03930953Phase 1/Phase 2 · active not recruiting A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL) · 260 trials list this drug (128 active) | — | — | Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05336812Phase 2 · recruiting Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia · 260 trials list this drug (128 active) | — | — | Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03332017Phase 2 · completed A Study Comparing Obinutuzumab and BGB-3111 Versus Obinutuzumab Alone in Treating R/R Follicular Lymphoma · 260 trials list this drug (128 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03580928Phase 2 · active not recruiting Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL · 260 trials list this drug (128 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04883437Phase 2 · recruiting Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas · 260 trials list this drug (128 active) | — | — | Indolent Non-Hodgkin Lymphoma,Mantle Cell Lymphoma,Grade 1 Follicular Lymphoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04895436Phase 2 · recruiting Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL) · 260 trials list this drug (128 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07107490Phase 1 · recruiting A PHASE I STUDY OF ALPS12 IN PATIENTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCER · 260 trials list this drug (128 active) | — | — | Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06357676Phase 1/Phase 2 · recruiting Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial · 260 trials list this drug (128 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04855695Phase 1/Phase 2 · recruiting Avo In R/R And Previously Untreated MCL · 260 trials list this drug (128 active) | — | — | Lymphoma,Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06333262Phase 2 · recruiting Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia · 260 trials list this drug (128 active) | — | — | Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02896582Phase 2 · completed Efficacy of Upfront and Maintenance Obinutuzumab in Mantle Cell Lymphoma Treated by DHAP and MRD Driven Maintenance · 260 trials list this drug (128 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05211336Phase 1 · active not recruiting Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma Involving the Central Nervous System · 260 trials list this drug (128 active) | — | — | Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07326371Phase 2 · not yet recruiting Glofitamab Combined With CAR-T Therapy in R/R DLBCL · 260 trials list this drug (128 active) | — | — | Interdigitating Dendritic Cell Sarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04843904Phase 1 · active not recruiting Safe Accelerated Venetoclax Escalation in CLL · 260 trials list this drug (128 active) | — | — | Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06043674Phase 2 · recruiting Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation · 260 trials list this drug (128 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06054776Phase 2 · recruiting Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma · 260 trials list this drug (128 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02296918Phase 1 · completed Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL · 260 trials list this drug (128 active) | — | — | Chronic Lymphocytic Leukemia,Prolymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05364424Phase 1 · completed A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Participants With Relapsed/Refractory Transplant or CAR-T Therapy Eligible Diffuse B-Cell Lymphoma · 260 trials list this drug (128 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02666898Phase 2 · completed Phase II Trial GA101 Inbrutinib B CLL · 260 trials list this drug (128 active) | — | — | Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07240194Phase 2 · recruiting The Efficacy and Safety of Glofitamab in Combination With PD-1 Antibody and Lenalidomide in Patients With Relapsed/Refractory Large B-cell Lymphoma (LBCL) With TP53 Aberrations: A Prospective, Multicenter, Phase II Clinical Study · 260 trials list this drug (128 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06916767Phase 1 · recruiting Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma · 260 trials list this drug (128 active) | — | — | Lymphoma,Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02242942Phase 3 · completed Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia · 260 trials list this drug (128 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05943496Phase 1 · recruiting Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma · 260 trials list this drug (128 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05105841Phase 2 · completed Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) · 260 trials list this drug (128 active) | — | — | Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02315768Phase 1/Phase 2 · completed Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients. · 260 trials list this drug (128 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03039114Phase 1 · completed Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102) · 260 trials list this drug (128 active) | — | — | Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06978088Phase 2 · recruiting LP-168 and Obinutuzumab for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Variants of This · 260 trials list this drug (128 active) | — | — | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma,Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02393157Phase 2 · recruiting Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL · 260 trials list this drug (128 active) | — | — | Non-Hodgkin Lymphoma,Burkitt Lymphoma,Diffuse Large B-Cell Lymphoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03401853Phase 2 · terminated Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma · 260 trials list this drug (128 active) | — | — | Diffuse Large B-Cell Lymphoma,Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04826003Phase 1 · completed Study To Evaluate Safety, Pharmacokinetics, Pharmacodynamics, And Preliminary Anti-Tumor Activity Of RO7122290 In Combination With Cibisatamab With Obinutuzumab Pre-Treatment · 260 trials list this drug (128 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01995669Phase 1/Phase 2 · completed Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma · 260 trials list this drug (128 active) | — | — | Small Lymphocytic Lymphoma,Follicular Lymphoma,Grade 3 Follicular Lymphoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02750670Phase 2 · completed Obinutuzumab in Combination With GDP Chemotherapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma · 260 trials list this drug (128 active) | — | — | Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06351527Phase 1 · recruiting Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ICP-248 as Monotherapy or in Combination With Anti-CD20 Monoclonal Antibody in Mature B-cell Malignancies · 260 trials list this drug (128 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02457598Phase 1 · terminated Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies · 260 trials list this drug (128 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02871219Phase 2 · completed Obinutuzumab and Lenalidomide in Treating Patients With Previously Untreated Stage II-IV Grade 1-3a Follicular Lymphoma · 260 trials list this drug (128 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07003464Phase 2 · not yet recruiting Phase II Trial of Zanubrutinib, Obinutuzumab, Bendamustine (ZGB) as First-Line Therapy for Chronic Lymphocytic Leukemia: A Single-Center Study · 260 trials list this drug (128 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03432741Phase 1 · terminated Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer · 260 trials list this drug (128 active) | — | — | Breast Carcinoma,Hodgkin Lymphoma,Non-Hodgkin Lymphoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04034056completed Untreated FolliculaR Lymphoma Treated With OBinituzumAb in a Non-interventional Study (URBAN) · 260 trials list this drug (128 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06961500Phase 2 · not yet recruiting Obinutuzumab With CHOP Versus Obinutuzumab With Bendamustine in the Treatment of Newly Diagnosed Follicular Lymphoma Grade 3A · 260 trials list this drug (128 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04464798Phase 1 · terminated A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas · 260 trials list this drug (128 active) | — | — | Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04578600Phase 1 · completed CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma · 260 trials list this drug (128 active) | — | — | B-Cell Non-Hodgkin Lymphoma,Hairy Cell Leukemia,Chronic Lymphocytic Leukemia+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04920968Phase 2 · recruiting Obinutuzumab Versus Rituximab for Acute Lymphoblastic Leukemia/PALG ALL7 "OVERALL" · 260 trials list this drug (128 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03492125Phase 1/Phase 2 · terminated A Study Of The Selective PKC-β Inhibitor MS- 553 · 260 trials list this drug (128 active) | — | — | Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma,Aggressive Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04962126Phase 2 · active not recruiting Frontline Treatment of Follicular Lymphoma With AtezolizUmab and Obinutuzumab With and Without RadiOtherapy · 260 trials list this drug (128 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04880863Phase 2 · completed NAP in Combination With Docetaxel Following Obinutuzumab Pretreatment in Subjects With Checkpoint Inhibitor Pretreated Advanced or Metastatic NSCLC · 260 trials list this drug (128 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04599634Phase 1 · completed Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies · 260 trials list this drug (128 active) | — | — | B-Cell Malignant Neoplasm,Follicular Lymphoma,Mantle Cell Lymphoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03467373Phase 1 · completed A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL · 260 trials list this drug (128 active) | — | — | B-Cell Malignant Neoplasm,Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02950051Phase 3 · completed Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation · 260 trials list this drug (128 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03787264Phase 2 · completed Sequential Regimen of Bendamustin-Debulking Followed by Obinutuzumab, Acalabrutinib and Venetoclax in Patients With Relapsed/Refractory CLL · 260 trials list this drug (128 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03836261Phase 3 · active not recruiting Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL · 260 trials list this drug (128 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06071871Phase 2 · recruiting A Trial of Polatuzumab Vedotin, Obinutuzumab and Glofitamab As a Peri-CAR-T Cell Treatment Strategy in Large B-cell Lymphoma · 260 trials list this drug (128 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02612311Phase 3 · terminated Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic Leukemia · 260 trials list this drug (128 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03890289Phase 2 · terminated Idelalisib+Obinutuzumab in Patients With Relapsed/Refractory Follicular Lymphoma · 260 trials list this drug (128 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06656221Phase 2 · not yet recruiting A Prospective, Single-Center Study Evaluating the Efficacy and Safety of Glofitamab Combined With Orelabrutinib and Bortezomib in Patients With High-Risk Mantle Cell Lymphoma · 260 trials list this drug (128 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04787042Phase 1/Phase 2 · recruiting Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067 · 260 trials list this drug (128 active) | — | — | Malignant Neoplasm,Solid Neoplasm,Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02569476Phase 1 · completed BGB 3111 in Combination With Obinutuzumab in Participants With B-Cell Lymphoid Malignancies · 260 trials list this drug (128 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03311126Phase 2 · terminated Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell Lymphoma · 260 trials list this drug (128 active) | — | — | Non-Hodgkin Lymphoma,Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06656234not yet recruiting The Effectiveness and Safety of Glofitamab in Real-World Clinical Practice Among Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Prospective, Observational, Multicenter Study · 260 trials list this drug (128 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02529852Phase 1/Phase 2 · completed A Phase I/II Study of Lenalidomide and Obinutuzumab With CHOP for Diffuse Large B Cell Lymphoma · 260 trials list this drug (128 active) | — | — | Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05219513Phase 1 · terminated A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7443904 in Combination With Glofitamab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma · 260 trials list this drug (128 active) | — | — | Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06567366Phase 2 · not yet recruiting CAR T-cell Therapy in Combination With Glofitamab for Relapsed/Refractory Large B-Cell Lymphoma With High-Risk Prognostic Factors · 260 trials list this drug (128 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03866239Phase 1 · terminated A Phase Ib Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Cibisatamab in Combination With Atezolizumab After Pretreatment With Obinutuzumab in Participants With Previously Treated Metastatic Colorectal Adenocarcinoma · 260 trials list this drug (128 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06547944Phase 1 · active not recruiting Zanubrutinib, Obinutuzumab and Lenalidomide in Newly Diagnosed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) · 260 trials list this drug (128 active) | — | — | Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03406156Phase 3 · completed A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy · 260 trials list this drug (128 active) | — | — | Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03980171Phase 1/Phase 2 · active not recruiting Study of Lenalidomide, Venetoclax and Obinutuzumab in Patients With Treatment-Naïve Follicular Lymphoma · 260 trials list this drug (128 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04434196Phase 1 · completed A Safety and Preliminary Efficacy Study of CC-99282 in Combination With Obinutuzumab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma · 260 trials list this drug (128 active) | — | — | Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06474481Phase 2 · not yet recruiting Zanubrutinib and G-CHOP in Untreated Intermediate-high Risk Follicular Lymphoma · 260 trials list this drug (128 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04722601Phase 1/Phase 2 · terminated A Dose-Finding and Efficacy Study of Venetoclax, CC-486, and Obinutuzumab in Follicular Lymphoma · 260 trials list this drug (128 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05950997NA · recruiting A Single Arm Study of Acalabrutinib Conbimed With Obinutuzumab in Chinese Patients With Previously Untreated CLL · 260 trials list this drug (128 active) | — | — | Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05894447Phase 1 · withdrawn Naptumomab Estafenatox in Combination With Pembrolizumab Preceded by Obinutuzumab in Patients With Urothelial Cancers · 260 trials list this drug (128 active) | — | — | Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03817853Phase 4 · completed An Open-Label, Single Arm Study of Obinutuzumab Short Duration Infusion in Patients With Previously Untreated Advanced Follicular Lymphoma · 260 trials list this drug (128 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04313608Phase 1 · completed A Study Evaluating the Safety and Efficacy of Glofitamab or Mosunetuzumab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and High-Grade Large B-Cell Lymphoma · 260 trials list this drug (128 active) | — | — | B-Cell Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05387616Phase 2 · unknown A Prospective Multicenter Phase 2 Study of the Chemotherapy-Free Combination of the Intravenous Phosphatidylinositol-3-Kinase (PI3K) Inhibitor Copanlisib in Combination With Obinutuzumab in Patients With Previously Untreated Follicular Lymphoma (FL) and a High Tumor Burden · 260 trials list this drug (128 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04657302Phase 1 · completed A Study to Evaluate Glofitamab as Single Agent Administered After Pretreatment With Obinutuzumab in Chinese Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma · 260 trials list this drug (128 active) | — | — | Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05833763Phase 2 · recruiting A Phase 2 Trial of GlOfitamab anD pIrtobrutinib in Mantle Cell Lymphoma Patients With Prior BTK Inhibitor Exposure. · 260 trials list this drug (128 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02600897Phase 1/Phase 2 · completed A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) · 260 trials list this drug (128 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04023071Phase 1 · terminated FT516 in Subjects With Advanced Hematologic Malignancies · 260 trials list this drug (128 active) | — | — | B-Cell Malignant Neoplasm,Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04245722Phase 1 · terminated FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies · 260 trials list this drug (128 active) | — | — | B-Cell Malignant Neoplasm,Chronic Lymphocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02417285Phase 1 · completed A Phase 1b Open-label Study to Evaluate the Safety and Efficacy of CC-122 With Obinutuzumab (GA101) in Relapsed/Refractory DLBCL and iNHL. · 260 trials list this drug (128 active) | — | — | Lymphoma,Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02611323Phase 1/Phase 2 · completed A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL) · 260 trials list this drug (128 active) | — | — | Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02391545Phase 1/Phase 2 · terminated A Study of Duvelisib in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma (CONTEMPO) · 260 trials list this drug (128 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02962401Phase 2 · completed Efficacity of Idelalisib and Obinutuzumab in Patient With Relapsed Refractory Waldenstrom's Macroglobulinemia · 260 trials list this drug (128 active) | — | — | Waldenstrom Macroglobulinemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03229382Phase 2 · terminated Efficacy and Safety of Obinutuzumab Preemptive Treatment at the Time of the Molecular Relapse · 260 trials list this drug (128 active) | — | — | Mantle Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03010358Phase 1/Phase 2 · completed Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma · 260 trials list this drug (128 active) | — | — | B-Cell Prolymphocytic Leukemia,Hairy Cell Leukemia,Chronic Lymphocytic Leukemia+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05968001unknown Obinutuzumab in Chinese Real-world Patients With iNHL · 260 trials list this drug (128 active) | — | — | B-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05846750Phase 2 · recruiting Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Marginal Zone Lymphoma · 260 trials list this drug (128 active) | — | — | Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05899621recruiting A Real-world Study of Obinutuzumab-based Therapy for Previously Untreated FL · 260 trials list this drug (128 active) | — | — | Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03145480Phase 2 · terminated Study of Ibrutinib & Obinutuzumab With/Without CHOP for Richter's Transformation or Richter's Syndrome Patients · 260 trials list this drug (128 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05823701Phase 2 · unknown Chidamide, Azacitidine Combined With GM Regimen for Relapsed and Refractory DLBCL Patients · 260 trials list this drug (128 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05797948NA · unknown GZL Sequential CD19/CD22 CAR-T in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma · 260 trials list this drug (128 active) | — | — | B-Cell Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03492775Phase 2 · completed First Line Therapy of Advanced Stage Follicular Lymphoma in Patients < 60 Years Not Eligible fo Standard Immunochemotherapy and in All Patients ≥ 60 Years · 260 trials list this drug (128 active) | — | — | Indolent Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01992653Phase 1/Phase 2 · completed A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma · 260 trials list this drug (128 active) | — | — | Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02292225Phase 1 · terminated Duvelisib With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi (SYNCHRONY) · 260 trials list this drug (128 active) | — | — | Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02758665Phase 2 · completed Trial of Ibrutinib Plus Venetoclax Plus Obinutuzumab in Patients With CLL · 260 trials list this drug (128 active) | — | — | Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03374137completed Observational Study to Monitor Safety and Effectiveness of Obinutuzumab in Follicular Lymphoma or Previously Untreated Chronic Lymphocytic Leukemia · 260 trials list this drug (128 active) | — | — | Chronic Lymphocytic Leukemia,Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03276468Phase 2 · completed Evaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory Lymphomas · 260 trials list this drug (128 active) | — | — | Diffuse Large B-Cell Lymphoma,Follicular Lymphoma,Marginal Zone Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02257567Phase 1/Phase 2 · completed A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma · 260 trials list this drug (128 active) | — | — | Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04551352Phase 1 · completed A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas · 260 trials list this drug (128 active) | — | — | Cutaneous Melanoma,Uveal Melanoma,Mucosal Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02225275Phase 2 · terminated Lenalidomide and Obinutuzumab in Treating Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma · 260 trials list this drug (128 active) | — | — | Chronic Lymphocytic Leukemia,Small Lymphocytic Lymphoma | 1 | Observed | clinicaltrials | graph → |